1985, after more than three years' research, Hu Jiqiang and his team introduced Qianliekang, the world's first drug for treating prostatic hyperplasia, which was made of rape pollen, and won the collective gold medal at the 32nd International Beekeeping Congress and the 22nd International Bee Products Expo, which was also a major milestone in the development of Kangbain.
From 65438 to 0990, he presided over the development of another important product-Ginkgo biloba extract, which was first introduced by Kang in China and exported to the international market.
Subsequently, Hu Jiqiang led the R&D team to break through the technical bottleneck of Ginkgo biloba extraction process, and successfully developed Ginkgo biloba leaves for the first time in China. Finally, in 1992, Ginkgo biloba, the first modern plant medicine in China that meets international standards, was officially approved. 1993, "Tianbaoning" brand Ginkgo biloba capsules obtained the new drug certificate of the Ministry of Health as the first new drug of Ginkgo biloba extract.
The listing of "Tianbaoning" brand Ginkgo biloba capsules has once again attracted the attention of international and domestic markets to Kang Enbei. In order to better market Tianbaoning, Hu Jiqiang decided to set up a prescription drug marketing department in Hangzhou, and set up the first prescription drug promotion team of Kangenbei, making Kangenbei an earlier pharmaceutical company in China to promote prescription drugs academically. In the following three years, Hu Jiqiang quickly built Tianbaoning into one of the few products with a single variety and a single brand exceeding 100 million yuan.
"Qianliekang" brand Pulean tablets and "Tianbaoning" brand Ginkgo biloba capsules, as national protected varieties of traditional Chinese medicine, national famous brand products of traditional Chinese medicine, high-quality products of the State Administration of Traditional Chinese Medicine and high-quality products of Zhejiang Province, have become the first choice drugs in their respective treatment fields for more than 20 years with their remarkable curative effect and reliable quality, which has successfully established Kang's leading position in the field of modern botanical medicine in China and laid a solid foundation for enterprises to take modern botanical medicine as their development direction.
In the following years, Hu Jiqiang took the lead in putting forward the organic combination of traditional Chinese medicine technology and new preparations in China, and initiated and presided over the research and development of many innovative new drugs. After years of exploration, with the joint efforts of the company's scientific and technological personnel, the sustained-release preparation of traditional Chinese medicine and orally disintegrating preparation were developed and declared for the first time in China. This also provides a useful reference for other enterprises' product development concepts and effectively promotes the modernization process of traditional Chinese medicine.
In 2000, Hu Jiqiang invested in the establishment of Zhejiang Institute of Traditional Chinese Medicine and Natural Medicine, which is the first provincial private medical research institution in Zhejiang. Its main function is to make use of genuine medicinal resources in Zhejiang Province and use modern pharmaceutical technology for in-depth research and development.
Then, it was decided that Kang and the French company Aifa jointly invested 6.67 million US dollars to establish a drug R&D center, a Zhejiang branch of the National Medical Engineering Center, a Zhejiang Chiral Drug Center of Chengdu Institute of Organic Sciences of Chinese Academy of Sciences, and the largest plant drug extraction base in Zhejiang Province. These measures have had a considerable impact on the domestic pharmaceutical and business circles. Based on this, some commentators believe that Kang "has made outstanding contributions to the development of Chinese medicine and even the national medicine economy"
In business practice, Hu Jiqiang put forward the position that "modern plant medicine originated from Kang" and pointed out the industrial development direction of Kang after in-depth investigation of the domestic and international environment and the company's small environment. He believes that modern botanical medicine is an effective way for Chinese medicine to go international, and it is also the only way for Chinese medicine industry to connect with the international market. The core advantage of Kang industry is the research and development and production of modern plant medicine, not the production of traditional Chinese medicine. This foresight makes Kang always in a strategic position in the field of plant medicine in China.
Nowadays, the industrial chain of the plant medicine plate of Kang Group has been extended to the cultivation of medicinal plants, forming an industrial system with the pharmaceutical industry as the main part and the bio-agricultural industry, healthy food and health care for the elderly as the supplement. A grand picture with great health as the core and Jinhua Lanxi, the birthplace of Kang Bain, as the axis is slowly unfolding.